ArticleScientific reports2026
Pharmacological investigation of bergapten isolated from Glehnia littoralis against periodontitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is a periodontal disease that causes tooth loss in severe cases due to chronic inflammation. The role of ER stress in this process of periodontal inflammation has not been identified. Glehnia littoralis has been used to relieve inflammation in traditional Chinese medicine, and the effect of bergapten, a compound isolated from G. littoralis, on ER stress during the progression of periodontitis was evaluated. The efficacy of bergapten was evaluated in silico and in vitro using human periodontal ligament cells stimulated with Porphyromonas gingivalis-lipopolysaccharides (PG-LPS). The effects of bergapten were also demonstrated in two in vivo model on PG-LPS- and ligature-induced periodontitis animal models. In silico simulation revealed that bergapten bound to the active site and downregulated the gene expression levels of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1β, which are major inflammatory cytokines in periodontitis. Osteoblast differentiation was induced in human periodontal ligament cells stimulated with PG-LPS. These effects were confirmed to occur through the regulation of ER stress by bergapten. An in vivo study was conducted to support these in vitro results, and bergapten alleviated inflammatory infiltration and inflammatory cytokine expression levels, along with restoring periodontitis-induced periodontal tissue loss. This study reveals the novel physiological activity of bergapten and suggests its potential as a new periodontitis therapeutic agent that can reduce the side effects caused by various surgical treatments and therapies used to treat periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.